Aktive Positionen von Peter Vitins
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Axalbion SA | Direktor/Vorstandsmitglied | - | - |
Axalbion Therapeutics Ltd.
 Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Peter Vitins
Statistik
International
| Schweiz | 2 |
| Vereinigtes Königreich | 2 |
Operativ
| Director/Board Member | 2 |
Sektoral
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
| Axalbion SA | |
Axalbion Therapeutics Ltd.
Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | Health Technology |
- Börse
- Insiders
- Peter Vitins
- Erfahrung
